Univariate analysis showed that ovarian carcinoma patients with serum anti-p53 AAbs had significantly shorter disease-free survival than those without anti-p53 AAbs (P = .02) whereas overall survival was not significantly different. The gene discussed is TP53; the disease is ovarian carcinoma.